Healthcare

Glioblastoma Market

By Segment, By Region, And Segment Forecasts, 2016 – 2025

Vertical: HealthcareBase Year: 201812 Sections

Executive Summary

Glioblastoma Market — Snapshot

  • Market Size (2016)

    2016

    $884.70M

  • Projected (2025)

    2025

    $1.64B

  • CAGR (2016–2025)

    7.1%

    7.1%
  • Key Players

    104+

Glioblastoma is a type of brain tumor. The cells in glioblastoma resemble astrocyte cells that normally nurture and provide sustenance to the neurons as well as respond to the injury of the brain tissue. A stem cell or immature astrocyte is the cell of origin that attains a genetic abnormality and ultimately grows into an entire population of cancerous glioblastoma cells. This can spread quickly throughout the brain, overrunning normal brain cells.

Key Insight

The Glioblastoma Market market is projected to grow at a CAGR of 7.1% from 2016 to 2025.

Market Performance Trend

Historical performance and future projections (2020–2030, USD Billion)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Scope & Coverage

What this report covers

  • Geographic Coverage: This analysis covers 5 regions: Middle East and Africa, North America, Asia Pacific, Europe, South America.
  • Market Segmentation: The market is analyzed across 2 segments: Primary Glioblastoma, Secondary Glioblastoma. Forecasts are provided for each segment from 2016 to 2025.
  • Competitive Landscape: 104 leading companies are profiled, covering market positioning, strategies, and recent developments.

Market Size (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Overview

Glioblastoma Market — Growth Trajectory

Glioblastoma is a tumor that forms from star-shaped cells in the brain called astrocytes. The increasing occurrences of glioblastoma coupled with increasing research activities in glioblastoma treatment and rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market

Glioblastoma Market — Growth Trajectory

Primary Glioblastoma
Secondary Glioblastoma

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Size Trend (USD Mn)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Market Dimensions

How this market is segmented

  • Type Type is broken down into: Primary Glioblastoma, Secondary Glioblastoma.
  • Treatment Treatment is broken down into: Surgical Procedure, Radiation Therapy, Chemotherapy, Others.
  • End User End User is broken down into: Hospitals, Specialty Clinics & Centers, End User_Others.

Geographic Analysis

Regional market breakdown

  • Middle East and Africa Middle East and Africa market size reached $37.10M in 2016 and is projected to reach $63.00M by 2025, growing at a CAGR of 6.1%.
  • North America North America market size reached $332.90M in 2016 and is projected to reach $637.00M by 2025, growing at a CAGR of 7.5%.
  • Asia Pacific Asia Pacific market size reached $173.40M in 2016 and is projected to reach $317.90M by 2025, growing at a CAGR of 7.0%.
  • Europe Europe market size reached $297.70M in 2016 and is projected to reach $543.30M by 2025, growing at a CAGR of 6.9%.
  • South America South America market size reached $43.70M in 2016 and is projected to reach $82.20M by 2025, growing at a CAGR of 7.3%.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Research Methodology

Glioblastoma Market — How We Researched This Market

This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.

  • Base Year

    2018

  • Historical Period

    2016 – 2018

  • Forecast Period

    2018 – 2025

  • Primary Interviews

    150+

Research Process

Historical data (2016–2018) and forecast period (2018–2025)

1

Problem Definition

  • Market scoping
  • Objective setting
  • Framework design
2

Secondary Research

  • Literature review
  • Data mining
  • Trend analysis
3

Primary Research

  • Expert interviews
  • Field visits
  • Surveys
4

Data Analysis

  • Quantitative modeling
  • Statistical testing
  • Validation
5

Insights & Reporting

  • Synthesis
  • Recommendations
  • Visualization

Research Depth

Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.

Historical vs. Forecast Data

Historical (observed)
Forecast (modelled)

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Competitive Landscape & Porter's Five Forces

Glioblastoma Market — Competitive Analysis

Bargaining Power of Suppliers

Currently, the market consists of several players manufacturing novel drugs as well as generic drug producers. However, few existing key companies capture significant share in the market and have the capability of fluctuating the costs of the products. Another factor affecting the bargaining power of suppliers is the switching cost for buyers. Since there are a lot of generic drugs for the treatment of glioblastoma, this gives a moderate level of leverage to the buyers to switch. Furthermore, many companies are focusing on the development of new treatment options, which increases competition in the market. Therefore, the overall bargaining power of suppliers in the global glioblastoma market is moderate.

Bargaining Power of Buyers

The bargaining power of buyers is low to moderate in the global glioblastoma market. Patients are the primary buyers in the market through different distribution channels such as hospitals and retail pharmacies. The presence of buyers in the market is rising due to the increasing prevalence of glioblastoma and brain tumors. Also, some buyers are price-sensitive, which moderately affects their bargaining power in the market. The market is characterized by moderate availabilities of substitute products, which reduces the buying power to an extent.

Threat of New Entrants

The threat of new entrants is moderate in the global glioblastoma market due to the development of the potential market. Any company trying to enter the market has to get the product approved and certified by various regulatory authorities in different countries. The rising awareness regarding glioblastoma and its severity among the patients pushes the currently established and other manufacturers to focus more on its treatment alternatives. There is a stronghold of the big companies in this market, which can make the entry of the new players a bit difficult. Moreover, many key companies in the market have failed clinical trials after reaching phase III. This negatively affects the decision of medium-sized companies to enter into this market as they do not have much capital to invest in the field.

Threat of Substitutes

The threat of substitutes in the global glioblastoma market is moderate. The substitutes in the market constitute the generic versions of drugs available in the market. Although there are a moderate number of substitutes available in the market, the buyer’s propensity to substitute is low as most of the medical professionals prescribe a limited number of drugs for the treatment of glioblastoma. Additionally, quality, trust issues, and excellent service provided by the existing established players restrict the threat by the substitutes.

Intensity of Rivalry

The degree of competition in the global glioblastoma market is moderate to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the global glioblastoma market are trying to develop cost-effective products to make product differentiation more affordable. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.

Quantitative Analysis

Regional Breakdown

Regional market breakdown for Glioblastoma Market.

Regional Market Size (USD Mn)

Market estimates by geography (2025)

USD Mn

InsightNorth America leads with $637.00M by 2025.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Regional Market Data

REGION201620182025CAGRSHARE
Middle East and Africa$37.10M$51.10M$63.00M6.1%4%
North America$332.90M$467.10M$637.00M7.5%39%
Asia Pacific$173.40M$232.90M$317.90M7.0%19%
Europe$297.70M$414.30M$543.30M6.9%33%
South America$43.70M$61.70M$82.20M7.3%5%
Total$884.80M$1.23B$1.64B7.1%100%

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans

Segment Revenue (2025)

Primary Glioblastoma
Secondary Glioblastoma
0211422632843

Segment Market Share

  • Primary Glioblastoma90%
  • Secondary Glioblastoma10%

Total Market Size

$854.56M

Market by Segment (2025)

APPLICATIONREVENUE ($B)GROWTH RATEMARKET PENETRATION
Primary Glioblastoma$765.77M7.1%
85%
Secondary Glioblastoma$88.79M7.1%
40%

* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.

Subscribe to Wantstats

Unlock premium reports, insights, blogs, charts and more.

View Subscription Plans
Empower your Business
with Insights

Save over 20% on
Annual Subscription

See plans for professionals or small and medium businesses.

Wantstats analytics dashboard

Analytics

Glioblastoma Market — Key Findings

Analytical insights on Glioblastoma Market covering market dynamics, competitive landscape, and strategic outlook.

Key Analytical Findings

The Glioblastoma Market market is projected to reach $1.64B by 2025, growing at 7.1% CAGR. The Primary Glioblastoma segment holds the largest share.

Market Dynamics

Glioblastoma are malignant grade IV tumors. Glioblastoma are infiltrative and can invade into nearby areas of the brain. These tumors predominantly constitute abnormal astrocytic cells, but also may contain different types of blood vessels and dead cells. Factors such as increasing incidence rates of glioblastoma, growing research on glioblastoma and brain tumors, and rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth. On the other hand, upcoming treatment alternatives are expected to be a strong opportunity for the market.

Market Drivers

The increasing incidence rate of glioblastomas is expected to fuel the growth of the global glioblastomas market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastomas has an incidence rate of 3.19 per 100,000 persons in the US. Also, according to the statistics updated by American Brain Tumor Association in 2018, glioblastomas represents about 15% of all primary brain tumors.

Similarly, the American Association of Neurological Surgeons suggests that glioblastomas account for approximately 17% of the brain tumors (primary and metastatic). The increasing incidence rate indirectly increases the healthcare spending of the people as well as the government. This pushes the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma over the forecast period.

Market Opportunities

Since glioblastomas is recurrent, there is rigorous research going on in his field to search for new tools for the treatment of this type of tumor. Various researchers are trying to incorporate different approaches such as gene therapies and innovative immunotherapies for the better treatment of glioblastoma. One of them is the integration of proton therapy. Proton therapy is an advanced technology to deliver radiation treatment to cancerous tumors. Proton therapy has fewer side-effects as it delivers less radiation to healthy organs and tissues. In pediatric cancers, proton therapy has huge benefits such as good rate of curability, fewer side-effects than the standard radiation therapy, and reduction in the risk of development of secondary cancer. As it is painless and non-invasive, most patients retain a high quality of life at the time and after treatments. All these benefits provide a global recognition of proton therapy in the treatment of brain tumors. Scientists are currently working on it as this therapy can be used in conjunction with surgery or chemotherapy. Thus, this can create lucrative options for top companies in the future.

Market Restraints

The Brain Tumor Charity suggests that only 3.3% of the patients suffering from glioblastoma survive beyond two years and that glioblastoma is extremely difficult to treat as it spreads to other parts of the brain in a short period. A lot of major companies who have invested in the research and development of glioblastoma drugs are suffering from setbacks. For instance, in May 2019, Bristol Myers Squibb announced that its drug candidate CheckMate -498 did not meet the set primary endpoint. Similarly, in May 2016, Actelion announced the termination of a clinical study on the safety and tolerability of Macitentan in combination with dose-dense temozolomide in patients with recurrent glioblastoma. This elucidates a confusion for medium-sized players to enter the market, thus restraining the growth of the market. Also, the company who has a failed clinical trial history might be unsure about continuing in the market. All these factors are resulting in the monetary loss for these companies, thus hindering the growth of the market over the assessment period.

Strategic Outlook and Future Directions

Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.

Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.

Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.

Market Value by Segment (2025)

Value (USD Mn)
Primary Glioblastoma
Secondary Glioblastoma

Companies

Key companies profiled in Glioblastoma Market

Profiles of 104 companies operating in the Glioblastoma Market market, including revenue, employee count, and market positioning where available.

Showing 104 of 104 companies

Amgen Inc.

Amgen Inc.

Healthcare

Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.

Revenue$23.0B
Employees20,000
Market CapN/A
Founded1979
California, US
Teva Pharm

Teva Pharmaceutical Industries Ltd

Healthcare

Company Headquarters: Petah Tikva, Israel Founded: 1901 Workforce: 43,000+ Company Working: Teva Pharmaceutical Industries Ltd (Teva) is one of the leaders in pharmaceutical industries engaged in developing and providing services in generic medicines. The company has more than 1,800 molecules which are used to create an extensive variety of generic products in almost every therapeutic area. It is specialized in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics fields. It has more than 35,000 unique products, which is more than any other pharmaceutical company. Teva produced 120 billion tablets and capsules in 2017. Geographically, it operates in regions, namely, North America, Latin America, Europe, Japan, and South Korea. The company operates in more than 60 countries worldwide. It has 26 FDA approved plants, and 31 European Medicines Agency (EMA) approved plants worldwide.

Revenue$16.9B
Employees43,000
Market CapN/A
Founded1900
Petah Tikva, Israel
F. HOFFMAN

F. HOFFMANN-LA ROCHE LTD

Healthcare

Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.

Revenue$63.3B
EmployeesN/A
Market CapN/A
FoundedN/A
United States, North America
Sun Pharma

Sun Pharmaceutical Industries Ltd

Healthcare

Company Headquarters: Mumbai, India Founded: 1983 Workforce: ~30,000 Company Working: Sun Pharmaceutical Industries Ltd (Sun Pharma) is one of India’s top pharmaceutical companies. It is the world’s fourth-largest generic pharmaceutical company. The company has vertically integrated businesses, high economies of scale, and a highly-skilled team. Sun Pharma delivers high-quality and reasonable medicines trusted by customers in over 150 countries globally, such as the US, Canada, Brazil, Germany, France, Russia, Japan, and South Africa. It also has a specialty products portfolio which contains ten specialty products, out of which five are in the market, three are likely to be commercialized soon, and two are awaiting USFDA approvals. It has its products in various leading therapeutic areas such as diabetes, oncology, pain, autoimmune diseases, respiratory diseases, antibiotics and vaccines, cardiovascular, HIV, mental health, and antivirals. Sun Pharma sells its duloxetine and atorvastatin products under the brand name AZTOR.

Revenue$4.1B
Employees30,000
Market CapN/A
Founded1982
Mumbai, India
Novavax, I

Novavax, Inc.

Healthcare

Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa

Revenue$0.5B
Employees2,500
Market CapN/A
Founded1986
Maryland, US
Ology Bios

Ology Bioservices, Inc

Healthcare

Company Headquarters: Florida, US Founded: 1999 Workforce: ~800 Company Working: Ology Bioservices, Inc. is an integrated biopharmaceutical company that develops and manufactures biopharmaceuticals and medical devices. It specializes in cell therapy, gene therapy, viral vectors, antibodies, oncolytic viruses, biopharmaceutical manufacturing, and vaccines. It has collaboration and partnerships with recognized government agencies, namely the Department of Defense and Medical Countermeasures Advanced Development and Manufacturing, which support it in developing biodefense products. Moreover, it has decades of experience in developing, licensing, and manufacturing proteins, therapeutics, and vaccines. It develops products to offer both commercial customers and US governments. Furthermore, it is a wholly owned company of National Resilience, Inc. (US), and assisting Resilience through its services includes regulatory support from preclinical through licensure and cGMP manufacturing up to biosafety level 3 (BSL3).

RevenueN/A
Employees800
Market CapN/A
Founded1998
Florida, US
Page 1 of 18
Go to page

About the Author

Healthcare Research Team

Healthcare

Our healthcare desk at Wantstats is staffed by a mix of clinical-market analysts and a senior researcher who track drug approvals, device launches, and provider economics as they happen — not just at reporting time. Every figure in this report is checked against primary interviews, regulatory filings, and our own proprietary datasets before it goes to print.

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Glioblastoma Market

Starting from
$4,950